New pill aims to keep lymphoma away after CAR-T
NCT ID NCT07198373
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 42 times
Summary
This study tests whether taking zanubrutinib (a targeted cancer pill) for two years after CAR-T cell therapy can help keep non-Hodgkin B-cell lymphoma from coming back. About 40 adults whose cancer responded to CAR-T will receive the drug. The main goal is to see how many remain cancer-free after 24 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
zanubrutinib (a targeted cancer pill)
What this could lead to
If it works, this could help keep non-Hodgkin B-cell lymphoma in remission longer after CAR-T therapy, reducing the chance of relapse.
What could go wrong
This is a small, early-phase exploratory study (40 people) with no control group, so results may not be conclusive. Zanubrutinib can cause side effects like bleeding or infections.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.